MYC and metastatic neoplasm: Sex, age below 10 years, post-surgical residual disease, histological subtype, MYC and MYCN amplification, CSI dose reduction, omission of boosts, intensification with myeloablative courses, and presence or absence of metastatic disease did not impact prognosis.